Insider trade

Perspective Therapeutics (CATX): Director bought ~$16K

Robert F Iii Williamson, Director at Perspective Therapeutics, bought ~$16K of Perspective Therapeutics shares.

~$16K
Approx. value · 19K sh @ $0.84
28K
Holds after · shares reported
Traded
Nov 12, 2026
Filed
Nov 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 9, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  2. Nov 10, 20265% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 1.8%
  3. Nov 11, 2026Insider · 2 peopleInsiders: 2 purchases (~$43K)
  4. Nov 12, 2026 · this disclosureInsider · 5 insiders in a week, 2nd time since 2006Director purchased ~$16K of CATX shares in the open market

What came next

  1. Nov 12, 20265% stakeLantheus Holdings, Inc. filed an activist stake (13D) of 3.9%
  2. Nov 12, 2026Insider · 4 peopleInsiders: 4 purchases (~$70K)
  3. Nov 16, 20265% stakeCommodore Capital LP reported a passive stake (13G) of 5.5%
  4. Nov 16, 2026Insider · 5 insiders in a week, 2nd time since 2006Director purchased ~$14K of CATX shares in the open market
  5. Nov 17, 2026Insider · 5 insiders in a week, 2nd time since 2006Director purchased ~$21K of CATX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Perspective Therapeutics

For Perspective Therapeutics, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CATX page.

Other recent filings by Robert F Iii Williamson, Director

The full history of Robert F Iii Williamson, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Perspective Therapeutics (CATX) insider traded, and how much?

Robert F Iii Williamson, Director at Perspective Therapeutics, bought ~$16K of Perspective Therapeutics shares. 19K shares at $0.84, open market.

When did it happen, and when was it made public?

Traded: Nov 12, 2026. Filed: Nov 16, 2026. That is 4 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Perspective Therapeutics recently?

For Perspective Therapeutics, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the CATX page.

Does this mean CATX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Perspective Therapeutics

Everything OQRO holds on this company is on its CATX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data